"Syk Kinase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An SH2 domain-containing non-receptor tyrosine kinase that regulates signal transduction downstream of a variety of receptors including B-CELL ANTIGEN RECEPTORS. It functions in both INNATE IMMUNITY and ADAPTIVE IMMUNITY and also mediates signaling in CELL ADHESION; OSTEOGENESIS; PLATELET ACTIVATION; and vascular development.
Descriptor ID |
D000072377
|
MeSH Number(s) |
D08.811.913.696.620.682.725.650 D12.644.360.900 D12.776.476.913
|
Concept/Terms |
Syk Kinase- Syk Kinase
- Kinase, Syk
- SYK Tyrosine Kinase
- Kinase, SYK Tyrosine
- Tyrosine Kinase, SYK
- Spleen Tyrosine Kinase
- Kinase, Spleen Tyrosine
- Tyrosine Kinase, Spleen
|
Below are MeSH descriptors whose meaning is more general than "Syk Kinase".
Below are MeSH descriptors whose meaning is more specific than "Syk Kinase".
This graph shows the total number of publications written about "Syk Kinase" by people in this website by year, and whether "Syk Kinase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2008 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Syk Kinase" by people in Profiles.
-
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma. Future Oncol. 2023 04; 19(11):737-738.
-
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 01 26; 14:57-70.
-
Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-?B signaling. JCI Insight. 2022 08 08; 7(15).
-
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clin Cancer Res. 2020 07 15; 26(14):3546-3556.
-
HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol. 2010 Mar; 11(3):265-72.
-
Beta-glucan activates microglia without inducing cytokine production in Dectin-1-dependent manner. J Immunol. 2008 Mar 01; 180(5):2777-85.
-
Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol. 2008 Feb; 38(2):500-6.
-
Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity. 2005 Apr; 22(4):507-17.